Overview of the global high-density multiplexed diagnostic assays market
According to Technavio’s market research report, the global high-density multiplexed diagnostic assays market will grow rapidly at a CAGR of more than 15% by 2021. The increase in equipment rental agreements will be one of the key factors driving the market’s growth until the end of 2021. The in-vitro diagnostics (IVD) market depends on rental or leasing agreements to use instruments such as clinical chemistry analyzers, immunochemistry analyzers, and multiplexed diagnostic equipment. End-users with limited budgets find leasing as an effective and convenient purchasing alternative to procure high-cost instruments. The governments of countries across the world also support the lease or rental businesses by offering tax benefits and increasing the flexibility. It has been observed that around 70%-80% of businesses offer IVD instruments based on extended lease or rental agreements. This will boost the adoption of high-density multiplexed diagnostic assays to carry out a wide range of tests for the detection of blood disorders and body-fluid infections in patients.
Owing to the rising incidence of infectious diseases and cardiovascular diseases (CVD), the Americas accounted for the majority of the market shares during 2016. The region is witnessing an increase in CVDs cases such as hypertension, coronary, and heart disease. This increase in CVD coupled with the growing diabetes and prediabetes population, will propel the growth of the high-density multiplexed diagnostic assays market in the coming years.
Competitive landscape and key vendors
The high-density multiplexed diagnostic assays market is highly competitive due to the presence of numerous regional and global vendors. The vendors are increasingly focusing on the expansion of their product portfolio and geographical reach. Additionally, they are also making huge investments towards the acquisition of advanced technologies.
Key vendors in this market are -
- Thermo Fisher Scientific
- Abbott
- F. Hoffmann-La Roche
Other prominent vendors in the market include Agilent Technologies, Bio-Rad Laboratories, Erba Diagnostics, GOLD STANDARD DIAGNOSTICS, Hologic, Luminex, and Randox Laboratories.
Segmentation by product and analysis of the high-density multiplexed diagnostic assays market
- High-density multiplexed diagnostic assays
- Very high-density multiplexed diagnostic assays
The high-density multiplexed diagnostic assays (500-10,000 plex) are used for the detection and disease management of cancers. The sales volume of high-density multiplexed diagnostic assays was high during 2016 due to the rising prevalence of cancer. The demand for the high-density multiplexed diagnostic assay will continue to increase during the next four years due to its high efficiency and user preference for sample testing.
Segmentation by end-user and analysis of the high-density multiplexed diagnostic assays market
- Clinical diagnostic laboratories
- Hospitals and clinics
Majority of patients prefer hospitals and clinics over clinical diagnostic laboratories since they collaborate with several research and development centers and research institutes. The molecular diagnostic techniques carried out in hospitals reduce the overall disease burden by enabling early diagnosis of diseases. The market will witness significant growth in this end-user segment since hospitals and clinics are also involved in the development of personalized medicines.
Key questions answered in the report include
- What will the market size and the growth rate be in 2021?
- What are the key factors driving the global high-density multiplexed diagnostic assays market?
- What are the key market trends impacting the growth of the global high-density multiplexed diagnostic assays market?
- What are the challenges to market growth?
- Who are the key vendors in the global high-density multiplexed diagnostic assays market?
- What are the market opportunities and threats faced by the vendors in the global high-density multiplexed diagnostic assays market?
- What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
- What are the key outcomes of the five forces analysis of the global high-density multiplexed diagnostic assays market?
Technavio also offers customization on reports based on specific client requirement
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 06: Market segmentation by product
- High-density multiplexed diagnostic assays (500-10,000 plex)
- Very high-density multiplexed diagnostic assays (>10,000 plex)
- Market overview
PART 07: Market segmentation by end-user
- Market overview
- Clinical diagnostic laboratories
- Hospitals and clinics
PART 08: Geographical segmentation
- High-density multiplexed diagnostic assays market in Americas
- High-density multiplexed diagnostic assays market in EMEA
- High-density multiplexed diagnostic assays market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
- Market drivers
- Infectious diseases
- Oncology
- Autoimmune diseases
- Cardiac diseases
- Allergies
- Other application areas
- Market challenges
PART 11: Market trends
- Introduction of automated multiplexed PCR assays
- Higher adoption rate of molecular POCT
- Improved sensitivity for the detection systems
- Outsourcing from hospitals to reference laboratories
PART 12: Vendor landscape
- Competitive landscape analysis
PART 13: Key vendor analysis
- Thermo Fisher Scientific
- Abbott
- F. Hoffmann-La Roche
- Key companies to watch
- Other prominent vendors
PART 14: Appendix